Respiratory Inhalers Market by Product (Dry Powder Inhalers, Metered Dose Inhalers, Soft Mist Inhaler); by Patients (Paediatric, Adults); by Distribution Channel (Hospitals, Pharmacies, Respiratory Care Center, Online Pharmacies); by Region (North America, Europe, Asia-pacific, Latin America, Middle East Africa): Global Forecasts 2021 To 2027

The Global Respiratory Inhalers Market Size was valued at USD 34.1 Bn in 2020 and is expected to reach USD 53.1 Bn by 2027, with a growing CAGR of 7% during the forecast period.

Respiratory inhaler is a medical device that is used to transfer medicated formulation from the nose to the lungs or targeted part of the body. Respiratory inhalers are mostly used for asthma and Chronic Obstructive Pulmonary Disease (COPD). Inhalers provide the advantage of avoiding systemic exposure of drugs to the body while transferring drugs directly to the targeted area.

Respiratory Inhalers Market Size 

Respiratory Inhalers Market Dynamics

The driving factors for the global respiratory inhalers market include rise in prevalence of respiratory diseases, increase in air pollution and growing number of allergic patients. Moreover, growing government initiatives in spreading awareness regarding pollution control & respiratory diseases management and availability of inhalers for different respiratory conditions fuel the growth of respiratory inhalers industry. Growing demand for respiratory disease treatment options, ever growing geriatric population and rising awareness regarding early pulmonary diseases boost the growth of respiratory inhalers industry.

Further, growing collaborations of pharmaceutical and medical device companies and increasing number of manufacturing units leverage the growth of respiratory inhalers industry across the globe. However, lack of awareness regarding availability of respiratory diseases management products hinders the growth of the ecosystem.

Global Respiratory Inhalers Market Segmentation:

By Product

  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Soft Mist Inhaler

By Patients

  • Paediatric
  • Adults

By Distribution Channel

  • Hospitals
  • Pharmacies
  • Respiratory Care Center
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Based on product, metered dose inhalers accounted for the highest market share in 2020 and is expected to increase during forecast period due to proper provision of delivering specific quantity of medication to the patients

Based on product, respiratory inhalers market is segmented into dry powder inhalers, metered dose inhalers and soft mist inhalers. Metered dose inhaler held the largest market share in 2020 due to ease of administrating proper amount of medication and provide patient compliance. Moreover, growing aging population and respiration related complications fuels the growth of this segment in respiratory inhalers industry.

For instance, in April 2020, Lupin and Aptar announced the launch of first ever smart metered-dose inhalers device in the Indian market. The product is expected to launch with brand name ADHERO to treat chronic respiratory diseases track and would help to enhance the adherence to the prescribed therapy. Such inventions are expected to boost the growth of segment in respiratory inhalers industry.

Based on patients, adult patients held the largest market share in 2020 and is expected to increase during forecast period due to increase in number of adult patients

Based on patients, respiratory inhalers market is segmented into adults and paediatric. Adult patients accounted for the highest market share in 2020 due to growing number of adult patients associated with respiratory complications. Moreover, growing breathing complications, increase in number of allergic patients boost the growth of this segment in respiratory inhalers industry.

According to the lung diseases & respiratory health surveys, 1 in 7 adults have lungs diseases. Growing adoption of western lifestyle and increasing consumption of smoking is expected to trigger respiratory problems that uplifts the growth of respiratory inhalers industry.

Based on distribution channel, pharmacies are expected to dominate the market during forecast period owing to increase in number of pharmacies and ease of availability of products

Based on distribution channel, respiratory inhalers market is segmented into hospitals, pharmacies, respiratory care center, and online pharmacies. Pharmacies held the largest market share in 2020 and expected to increase more during the forecast period due to availability of large variety of products at a place and growing number of pharmacies.  

Based on geographical region, North America dominated the market in 2020 and expected to maintain same dominance during the forecast due to presence of major key players in this region

Based on geography, North America held the largest market share in 2020 due to increase in number of asthma cases and rising incidences of COPD in this region. Strong presence of key players in North America, high awareness regarding early respiratory disease diagnosis and advances in healthcare technology fuels the growth of the ecosystem.

According to the survey, the US is the earliest adopters of latest inhalers technology and Canada is experiencing the same adoption for respiratory inhalers. This uplifts the growth of market in this region.

Company Profiles and Competitive Intelligence

The key players operating in the respiratory inhalers market are:

  • Cipla
  • GSK
  • Novartis
  • Boehringer Ingelheim
  • Astrazeneca
  • Propeller Health
  • Beximco Pharmaceuticals
  • H&t Presspart
  • Cohero Health
  • Chiesi Farmaceutici
  • Mundipharma
  • 3m
  • Heltman Medikal
  • Adherium
  • Luckys Pharma
  • Amiko Digital Health
  • Teva Pharmaceutical Industries
  • Findair Sp. Z O. O.
  • Vectura Group
  • GlaxoSmithKline plc
  • Koninklijke Philips N.V.
  • Merck & Co., Inc
  • Omron Healthcare Europe B.V
  • PARI Medical Holding respiratory

The report also provides an in-depth analysis of respiratory inhalers market dynamics such as drivers, restraints, opportunities, and challenges


  • Growing advances in medical technology
  • Increase in prevalence of chronic respiratory diseases
  • Rising pulmonary diseases and healthcare spending
  • Rise in air pollution across world


  • Strict government regulations for product approval
  •  Lack of product awareness


  • Emergence of newer pulmonary diseases
  • Higher adoption of inhalers


  • Rising number of key market players
  • High inhalers cost and adoption of alternative therapies

COVID-19 Impact on the Respiratory Inhalers Market Analysis

Covid-19 has highly affected the industries in terms of growth, economy, health and mental wellbeing of every individual. In this challenging situation, every industry is trying to give the best services in terms of quality and safety. Covid-19 has positively impacted the growth of respiratory inhalers market. Sudden outbreak of covid led to increase in demand for inhalers across the globe.

Covid-19 affects the respiratory system and majorly breathing, this created demand for the need of respiratory inhalers in the market. Many pharmaceutical companies focused on manufacturing of inhalers across the globe. This leveraged the growth of the ecosystem.

The report also provides an in-depth analysis of key trends in Respiratory Inhalers market

  • Growing innovations in medical devices and an increase in developments in accurate dose delivery inhalers  
  • Increase in use of a combination of LABA/ICS inhalers for COPD 

The report also provides an in-depth analysis of recent news developments and investments

  • In March 2021, Sandoz Inc announced the distribution of brand and authorized generic of respiratory inhalation medicine Proventil®HFA. Proventil®HFA  consists of albuterol sulfate which is used to treat bronchospasm in patients in age group >4 years. This launch of Sandoz will help to grow respiratory portfolio and will make generic formulation available to patients at affordable price
  • In June 2020, Teva Pharmaceutical launched digital asthma and COPD rescue inhaler in US market, this inhaler has inbuilt sensors that connect to a phone that helps to manage COPD and asthma symptoms. The new product launch would help the company to maintain their digital inhaler portfolio for treating asthmatic patients.

The unique insights provided by this report also includes the following:

  • In-depth Value Chain Analysis
  • Opportunity Mapping
  • Sector Snapshot
  • Key Players Positioning Matrix
  • Regulatory Scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market Trends
  • Covid-19 Impact Analysis
  • Product Comparison
  • Pre & Post COVID 19 Impacts on Respiratory Inhalers Market
  • Competitive Landscape

Frequently Asked Questions (FAQs)

The global market was valued at USD 34.1 Bn in 2020 and is anticipated to reach USD 53.1 Bn by 2027.

The global market is estimated to grow at a compound annual growth rate (CAGR) of 7% during forecast period.

In the base year 2020, North America accounted for about ~35% share in the market

Lack of product awareness and strict government regulations for product approval restraint the growth of market.

As per expert opinions, increasing number of pulmonary diseases, growing awareness regarding respiratory products and government spending on healthcare will drive the growth of market.

Few key players include, but not limit up to: Cipla, Novartis, Gsk, Boehringer Ingelheim, Astrazeneca, Propeller Health, Beximco Pharmaceuticals, Cohero Health, H&t Presspart, Chiesi Farmaceutici, 3M, Mundipharma, Heltman Medikal, Luckys Pharma and Adherium

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

  1.  Introduction
    1. Product Outline
    2. What is Respiratory Inhaler?
    3. Analysis of Respiratory Inhalers Market
    4. Covid -19 Impact
    5. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
    6. Technology Overview
  2. Regulatory Landscape for Respiratory Inhalers Market
    1. Regulations and Standards
  3. Respiratory Inhalers Market by Product
    1. Dry Powder Inhalers
    2. Metered Dose Inhalers
    3. Soft Mist Inhalers
  4. Respiratory Inhalers Market by Patients
    1. Paediatric
    2. Adults
  5. Respiratory Inhalers Market by Distribution Channels
    1. Hospitals
    2. Pharmacies
    3. Respiratory Care Center
    4. Online Pharmacies
  6. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Italy
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Latin America
      1. Brazil
      2. Colombia
      3. Rest of Latin America
    5. Middle East Africa (MEA)
      1. GCC
      2. Rest of MEA
  7. Key Strategic Insights
  8. Market Analysis
    1. Emerging Technologies
    2. Opportunity Mapping
    3. Critical Success Factors
    4. Customer Preferences
  9. Key Market Trends / Recent Developments
  10. Competitive Scenario
    1. Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product Launches
    5. Strength of Product Portfolio
    6. Ranking of Key Players
    7. Presence of Players by Geographies
  11. Key global players
    1. Cipla
    2. Gsk
    3.  Novartis
    4. Boehringer Ingelheim
    5. Astrazeneca
    6. Propeller Health
    7. Beximco Pharmaceuticals
    8. H&t Presspart
    9. Cohero Health
    10. Chiesi Farmaceutici
    11. Mundipharma
    12. 3m
    13. Heltman Medikal
    14. Adherium
    15. Luckys Pharma

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization